NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









R3 Vascular Inc.

R3 Vascular Inc.

Private
Mountain View, CaliforniaHealthcare & Life Scienceshttps://www.r3vascular.com/

Last Round

Series B

May 9, 2024

Est. Valuation

$145M

Total Funding Raised

$104.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

R3 Vascular Inc. is a medical device company that develops bioresorbable, sirolimus-coated vascular scaffolds for the treatment of peripheral arterial disease.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

bioresorbable scaffolddrug-eluting scaffoldperipheral artery diseasePADbelow-the-knee interventionBTKvascular interventionbioresorbable stentdrug-eluting stentclinical trialsFDA IDEvascular surgeryinterventional cardiologymedical devicedissolvable stent

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

R3 Vascular Inc. Comps

Public and private peers based on sector, stage, and business model.

R3 Vascular Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

R3 Vascular Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 9, 2024
Series AOct 8, 2020

R3 Vascular Inc. Investors

Notable investors and investment history

R3 Vascular Inc. investors
InvestorRounds
Deerfield ManagementSeries B
415Series A, Series B
415 CapitalSeries B, Series A
Wexford CapitalSeries A
HBM PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 24, 2026

    Grew 18% QoQ, from 28 to 33 employees.

R3 Vascular Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

R3 Vascular Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about R3 Vascular Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMountain View, California
Employee Range33
Year Founded2019
Last FundingMay 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.